Online citations, reference lists, and bibliographies.
← Back to Search

Safety And Efficacy Of Lamivudine-zidovudine Combination Therapy In Zidovudine-experienced Patients : A Randomized Controlled Comparison With Zidovudine Monotherapy

S. Staszewski, C. Loveday, J. Picazo, P. Dellamonica, P. Skinhøj, M. Johnson, S. Danner, P. Harrigan, A. Hill, L. Verity, H. McDade
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Objective. —To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy. Design. —Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 weeks. Setting. —Patients from 32 hospitals in Europe were enrolled throughout a 1-year period. Patients. —Adult human immunodeficiency virus type 1 (HIV-1)—positive, zidovudine-experienced (≥24 weeks prior zidovudine) patients with CD4+cell counts between 0.10 and 0.40×109/L (100-400 cells/μL). Intervention. —Patients received either 200 mg of zidovudine every 8 hours, 150 mg of lamivudine every 12 hours plus zidovudine, or 300 mg of lamivudine every 12 hours plus zidovudine for 24 weeks. All patients were then allowed to receive zidovudine and open-label lamivudine combination therapy. Twelve patients withdrew because of adverse events during the 24-week treatment period. Main Outcome Measures. —Effcacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects. Results. —Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued zidovudine monotherapy during the first 24 weeks as documented by changes in CD4+cell counts (+0.04 vs +0.03 vs −0.02×109/L, respectively;P Conclusions. —In zidovudine-experienced HIV-1—infected patients, combination treatment with lamivudine and zidovudine is well tolerated and provides greater and more sustained increases in CD4+cell counts and decreases in viral load than continued zidovudine monotherapy.
This paper references
10.1056/NEJM198707233170401
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
10.7326/0003-4819-112-10-727
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial
M. Fischl (1990)
10.1056/NEJM199004053221401
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
P. Volberding (1990)
10.1002/JMV.1890370402
A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type‐1 infected patients treated with zidovudine
S. Kaye (1992)
10.7326/0003-4819-116-1-13
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
T. Meng (1992)
10.1056/NEJM199208273270901
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
J. Kahn (1992)
10.1056/NEJM199307293290501
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
D. Cooper (1993)
10.1073/PNAS.90.12.5653
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
M. Tisdale (1993)
10.1016/S0140-6736(94)90006-X
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
Ann Marie Swart (1994)
10.1001/JAMA.1994.03520060037029
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
P. Volberding (1994)
10.1016/0166-0934(94)90040-X
A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes.
B. van Gemen (1994)
10.1093/INFDIS/170.3.553
Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA.
H. J. Lin (1994)
10.1177/009286159402800308
Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary Measures
J. Dawson (1994)
10.1128/jcm.32.2.292-300.1994
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection
J. Mulder (1994)
10.7326/0003-4819-122-6-199503150-00001
Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy
R. D'Aquila (1995)
10.1038/NM0795-628
Targeting HIV reverse transcriptase in novel ways
M. Wainberg (1995)
10.1126/SCIENCE.7542804
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
B. Larder (1995)
10.1016/S0140-6736(95)90668-1
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count
C. Loveday (1995)
10.7326/0003-4819-122-8-199504150-00003
Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion
J. Mellors (1995)
10.1093/INFDIS/171.6.1411
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
R. Schuurman (1995)
10.1056/NEJM199512213332502
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
J. Eron (1995)
10.1093/INFDIS/171.6.1438
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
J. Pluda (1995)
10.1093/INFDIS/171.5.1166
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
R. van Leeuwen (1995)
10.1128/AAC.39.7.1624
Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
P. Boyer (1995)
10.7326/0003-4819-122-1-199501010-00004
Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease
M. Fischl (1995)
10.1126/science.271.5253.1282
Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase
M. Wainberg (1996)
10.1021/BI9516642
Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis.
V. Pandey (1996)
10.1056/NEJM199602153340703
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
W. O'brien (1996)
10.1093/INFDIS/173.6.1354
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
R. Schooley (1996)



This paper is referenced by
10.1016/S0140-6736(18)32462-0
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn (2019)
10.1002/cpdd.740
Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
T. P. Dumitrescu (2019)
Org Immune Control of HIV
M. Balasubramaniam (2019)
10.29328/journal.ijcmbt.1001001
Oral Candida colonization in HIV-infected patients: Species and antifungal susceptibility in Tripoli/Libya
H Mohamed (2018)
10.1097/QAI.0000000000001660
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
R. Quercia (2018)
The effectiveness of first line antiretroviral therapy and the impact of micronutrient levels on patients' response to treatment in Windhoek, Namibia
N. Frans (2017)
Kinase Inhibitors and Nucleoside Analogues as Novel Therapies to Inhibit HIV-1 or ZEBOV Replication
S. McCarthy (2017)
10.1071/SH16190
Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new.
J. D'costa (2017)
Immunodeficiency Virus-Infected Patients Zidovudine, and Didanosine in Human Population Pharmacokinetics of Nevirapine,
V. Johnson (2013)
10.2165/00019053-199712010-00006
Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection
J. Chancellor (2012)
The investigation of genotypic antiretroviral drug resistance in the context of the South African national antiretroviral roll-out programme
V. Zyl (2012)
10.1111/j.1365-2710.2010.01235.x
Evaluation of steady‐state pharmacokinetic interactions between ritonavir‐boosted BILR 355, a non‐nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects
F. Huang (2012)
10.2165/00019053-199915001-00004
A Prospective Evaluation of the Cost Effectiveness of Adding Lamivudine to Zidovudine-Containing Antiretroviral Treatment Regimens in HIV Infection
L. Lacey (2012)
Intérêt du traitement antirétroviral précoce chez l’adulte infecté par le VIH en Afrique sub-Saharienne
Desmorys Raoul Moh (2012)
10.2165/00019053-199915001-00002
Lamivudine Reduces Healthcare Resource Use when Added to Zidovudine-Containing Regimens in Patients with HIV Infection
L. Lacey (2012)
10.1517/14656566.2012.642865
Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection
Maxwell O Akanbi (2012)
10.2165/00063030-199708040-00001
Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment
M. Koot (2012)
10.1097/QAI.0b013e31820bd2b6
Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana
S. Dryden-Peterson (2011)
10.1517/17425250903490418
Lamivudine for the treatment of HIV
P. Kumar (2010)
10.1016/S0140-6736(08)60624-8
Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
A. Phillips (2008)
10.1016/j.transproceed.2008.05.071
Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches.
A. Avolio (2008)
10.1016/j.mito.2008.01.002
Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver.
V. Desai (2008)
The renaissance of fixed dose combinations: Combivir
S. Portsmouth (2007)
10.1016/B0-08-045044-X/00213-3
Ribonucleic Acid Viruses: Antivirals for Human Immunodeficiency Virus
T. Lyle (2007)
Disease management--constructing optimal NRTI-based combinations: past, present, and future.
D. Dieterich (2006)
10.1186/1758-2652-8-1-16
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future
D. Dieterich (2006)
10.1016/J.ANTIVIRAL.2006.03.012
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.
R. Schinazi (2006)
10.1007/978-1-59745-085-0_2
Zidovudine, Lamivudine, and Abacavir
M. Carten (2006)
10.1016/J.JPBA.2005.05.002
Simultaneous determination of HIV-protease inhibitors lamivudine and zidovudine in pharmaceutical formulations by micellar electrokinetic chromatography.
R. Sekar (2005)
10.1310/WKTK-QFPB-XAEE-92M0
Evaluation of Multiple Failure Time Analyses of Observational Data in Patients Treated for HIV
Hyun Ja Lim (2005)
10.1016/J.IJANTIMICAG.2003.08.008
Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.
J. E. Eiros Bouza (2004)
10.1007/978-3-0348-7869-2_2
A perspective of the history of HAART
D. Konopnicki (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar